Shares of Daxor Co. (NYSEAMERICAN:DXR) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $8.74. Daxor shares last traded at $8.74, with a volume of 350 shares.
DXR has been the subject of several analyst reports. Ascendiant Capital Markets initiated coverage on Daxor in a report on Thursday, May 16th. They issued a “buy” rating and a $20.00 price objective for the company. Maxim Group initiated coverage on Daxor in a report on Monday, July 29th. They issued a “buy” rating and a $22.00 price objective for the company.
A hedge fund recently bought a new stake in Daxor stock. Shine Investment Advisory Services Inc. purchased a new position in shares of Daxor Co. (NYSEAMERICAN:DXR) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 45,454 shares of the company’s stock, valued at approximately $512,000. Shine Investment Advisory Services Inc. owned 1.22% of Daxor as of its most recent filing with the Securities & Exchange Commission.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.
See Also: Compound Interest
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.